CRISPR Therapeutics (NASDAQ: CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today reviewed recent progress in the clinical development programs for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot FDA News Management Comments

CRISPR Therapeutics (CRSP) Misses Q4 EPS by 14c; Provides Business UpdateFebruary 25, 2019 8:14 AM CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001February 25, 2019 8:01 AM